Intestinal metaplasia recurs infrequently in patients successfully treated for Barrett's Esophagus with radiofrequency ablation

Eric Orman, Hannah P. Kim, William J. Bulsiewicz, Cary C. Cotton, Evan S. Dellon, Melissa B. Spacek, Xiaoxin Chen, Ryan D. Madanick, Sarina Pasricha, Nicholas J. Shaheen

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

OBJECTIVES:Radiofrequency ablation (RFA) of Barrett's esophagus (BE) is safe and effective in eradicating dysplasia and intestinal metaplasia, and may reduce rates of esophageal adenocarcinoma (EAC). We assessed rates of and risk factors for disease recurrence after successful treatment of BE with RFA.METHODS:We performed a retrospective cohort study of patients who completed RFA for dysplastic BE or intramucosal carcinoma (IMC), achieved complete eradication of dysplasia (CE-D) or intestinal metaplasia (CE-IM), and underwent subsequent endoscopic surveillance at a single center. Rates of disease recurrence and progression were determined. Patients with and without recurrent disease were compared to determine risk factors for recurrence.RESULTS:Two hundred and sixty-two subjects underwent RFA during the study period. Of these, 119 and 112 patients were retained in endoscopic surveillance after CE-D and CE-IM, respectively. Median observation time was 397 days (range: 54-1,668 days). Eight patients (7% of those with CE-IM) had recurrent disease after a median of 235 days (range 55-1,124 days). Progression to IMC (n=1) or EAC (n=2) occurred in three of these eight patients, all of whom had pre-ablation high-grade dysplasia (HGD). Five patients had recurrence of non-dysplastic BE (n=3), low-grade dysplasia (n=1), and HGD (n=1). During 155 patient-years of observation, recurrence occurred in 5.2%/year, and progression occurred in 1.9%/year. No clinical characteristics were associated with disease recurrence.CONCLUSIONS:In patients with BE and dysplasia or early cancer who achieved CE-IM, BE recurred in ∼5%/year. Patient characteristics did not predict recurrence. Subjects undergoing RFA for dysplastic BE should be retained in endoscopic surveillance.

Original languageEnglish (US)
Pages (from-to)187-195
Number of pages9
JournalAmerican Journal of Gastroenterology
Volume108
Issue number2
DOIs
StatePublished - Feb 2013
Externally publishedYes

Fingerprint

Barrett Esophagus
Metaplasia
Recurrence
Adenocarcinoma
Observation
Carcinoma
Disease Progression
Cohort Studies
Retrospective Studies

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Intestinal metaplasia recurs infrequently in patients successfully treated for Barrett's Esophagus with radiofrequency ablation. / Orman, Eric; Kim, Hannah P.; Bulsiewicz, William J.; Cotton, Cary C.; Dellon, Evan S.; Spacek, Melissa B.; Chen, Xiaoxin; Madanick, Ryan D.; Pasricha, Sarina; Shaheen, Nicholas J.

In: American Journal of Gastroenterology, Vol. 108, No. 2, 02.2013, p. 187-195.

Research output: Contribution to journalArticle

Orman, E, Kim, HP, Bulsiewicz, WJ, Cotton, CC, Dellon, ES, Spacek, MB, Chen, X, Madanick, RD, Pasricha, S & Shaheen, NJ 2013, 'Intestinal metaplasia recurs infrequently in patients successfully treated for Barrett's Esophagus with radiofrequency ablation', American Journal of Gastroenterology, vol. 108, no. 2, pp. 187-195. https://doi.org/10.1038/ajg.2012.413
Orman, Eric ; Kim, Hannah P. ; Bulsiewicz, William J. ; Cotton, Cary C. ; Dellon, Evan S. ; Spacek, Melissa B. ; Chen, Xiaoxin ; Madanick, Ryan D. ; Pasricha, Sarina ; Shaheen, Nicholas J. / Intestinal metaplasia recurs infrequently in patients successfully treated for Barrett's Esophagus with radiofrequency ablation. In: American Journal of Gastroenterology. 2013 ; Vol. 108, No. 2. pp. 187-195.
@article{840b0406bfe94629a23cacbffb2b292b,
title = "Intestinal metaplasia recurs infrequently in patients successfully treated for Barrett's Esophagus with radiofrequency ablation",
abstract = "OBJECTIVES:Radiofrequency ablation (RFA) of Barrett's esophagus (BE) is safe and effective in eradicating dysplasia and intestinal metaplasia, and may reduce rates of esophageal adenocarcinoma (EAC). We assessed rates of and risk factors for disease recurrence after successful treatment of BE with RFA.METHODS:We performed a retrospective cohort study of patients who completed RFA for dysplastic BE or intramucosal carcinoma (IMC), achieved complete eradication of dysplasia (CE-D) or intestinal metaplasia (CE-IM), and underwent subsequent endoscopic surveillance at a single center. Rates of disease recurrence and progression were determined. Patients with and without recurrent disease were compared to determine risk factors for recurrence.RESULTS:Two hundred and sixty-two subjects underwent RFA during the study period. Of these, 119 and 112 patients were retained in endoscopic surveillance after CE-D and CE-IM, respectively. Median observation time was 397 days (range: 54-1,668 days). Eight patients (7{\%} of those with CE-IM) had recurrent disease after a median of 235 days (range 55-1,124 days). Progression to IMC (n=1) or EAC (n=2) occurred in three of these eight patients, all of whom had pre-ablation high-grade dysplasia (HGD). Five patients had recurrence of non-dysplastic BE (n=3), low-grade dysplasia (n=1), and HGD (n=1). During 155 patient-years of observation, recurrence occurred in 5.2{\%}/year, and progression occurred in 1.9{\%}/year. No clinical characteristics were associated with disease recurrence.CONCLUSIONS:In patients with BE and dysplasia or early cancer who achieved CE-IM, BE recurred in ∼5{\%}/year. Patient characteristics did not predict recurrence. Subjects undergoing RFA for dysplastic BE should be retained in endoscopic surveillance.",
author = "Eric Orman and Kim, {Hannah P.} and Bulsiewicz, {William J.} and Cotton, {Cary C.} and Dellon, {Evan S.} and Spacek, {Melissa B.} and Xiaoxin Chen and Madanick, {Ryan D.} and Sarina Pasricha and Shaheen, {Nicholas J.}",
year = "2013",
month = "2",
doi = "10.1038/ajg.2012.413",
language = "English (US)",
volume = "108",
pages = "187--195",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Intestinal metaplasia recurs infrequently in patients successfully treated for Barrett's Esophagus with radiofrequency ablation

AU - Orman, Eric

AU - Kim, Hannah P.

AU - Bulsiewicz, William J.

AU - Cotton, Cary C.

AU - Dellon, Evan S.

AU - Spacek, Melissa B.

AU - Chen, Xiaoxin

AU - Madanick, Ryan D.

AU - Pasricha, Sarina

AU - Shaheen, Nicholas J.

PY - 2013/2

Y1 - 2013/2

N2 - OBJECTIVES:Radiofrequency ablation (RFA) of Barrett's esophagus (BE) is safe and effective in eradicating dysplasia and intestinal metaplasia, and may reduce rates of esophageal adenocarcinoma (EAC). We assessed rates of and risk factors for disease recurrence after successful treatment of BE with RFA.METHODS:We performed a retrospective cohort study of patients who completed RFA for dysplastic BE or intramucosal carcinoma (IMC), achieved complete eradication of dysplasia (CE-D) or intestinal metaplasia (CE-IM), and underwent subsequent endoscopic surveillance at a single center. Rates of disease recurrence and progression were determined. Patients with and without recurrent disease were compared to determine risk factors for recurrence.RESULTS:Two hundred and sixty-two subjects underwent RFA during the study period. Of these, 119 and 112 patients were retained in endoscopic surveillance after CE-D and CE-IM, respectively. Median observation time was 397 days (range: 54-1,668 days). Eight patients (7% of those with CE-IM) had recurrent disease after a median of 235 days (range 55-1,124 days). Progression to IMC (n=1) or EAC (n=2) occurred in three of these eight patients, all of whom had pre-ablation high-grade dysplasia (HGD). Five patients had recurrence of non-dysplastic BE (n=3), low-grade dysplasia (n=1), and HGD (n=1). During 155 patient-years of observation, recurrence occurred in 5.2%/year, and progression occurred in 1.9%/year. No clinical characteristics were associated with disease recurrence.CONCLUSIONS:In patients with BE and dysplasia or early cancer who achieved CE-IM, BE recurred in ∼5%/year. Patient characteristics did not predict recurrence. Subjects undergoing RFA for dysplastic BE should be retained in endoscopic surveillance.

AB - OBJECTIVES:Radiofrequency ablation (RFA) of Barrett's esophagus (BE) is safe and effective in eradicating dysplasia and intestinal metaplasia, and may reduce rates of esophageal adenocarcinoma (EAC). We assessed rates of and risk factors for disease recurrence after successful treatment of BE with RFA.METHODS:We performed a retrospective cohort study of patients who completed RFA for dysplastic BE or intramucosal carcinoma (IMC), achieved complete eradication of dysplasia (CE-D) or intestinal metaplasia (CE-IM), and underwent subsequent endoscopic surveillance at a single center. Rates of disease recurrence and progression were determined. Patients with and without recurrent disease were compared to determine risk factors for recurrence.RESULTS:Two hundred and sixty-two subjects underwent RFA during the study period. Of these, 119 and 112 patients were retained in endoscopic surveillance after CE-D and CE-IM, respectively. Median observation time was 397 days (range: 54-1,668 days). Eight patients (7% of those with CE-IM) had recurrent disease after a median of 235 days (range 55-1,124 days). Progression to IMC (n=1) or EAC (n=2) occurred in three of these eight patients, all of whom had pre-ablation high-grade dysplasia (HGD). Five patients had recurrence of non-dysplastic BE (n=3), low-grade dysplasia (n=1), and HGD (n=1). During 155 patient-years of observation, recurrence occurred in 5.2%/year, and progression occurred in 1.9%/year. No clinical characteristics were associated with disease recurrence.CONCLUSIONS:In patients with BE and dysplasia or early cancer who achieved CE-IM, BE recurred in ∼5%/year. Patient characteristics did not predict recurrence. Subjects undergoing RFA for dysplastic BE should be retained in endoscopic surveillance.

UR - http://www.scopus.com/inward/record.url?scp=84873530943&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873530943&partnerID=8YFLogxK

U2 - 10.1038/ajg.2012.413

DO - 10.1038/ajg.2012.413

M3 - Article

C2 - 23247578

AN - SCOPUS:84873530943

VL - 108

SP - 187

EP - 195

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 2

ER -